Aisling Capital related stories
All articles and analysis
peHUB Wire: Friday, June 5, 2009Random Ramblings
- Xanodyne Pharma Raises $38 Million, Names New CEO
Xanodyne Pharmaceuticals Inc., a Florence, Ky.-based drug company, has raised $38 million in new VC funding led by MPM Capital. Return backers include AIG Investments, Aisling Capital, Blue Chip Venture Co., Essex Woodlands Health Ventures, HealthCare Ventures and Union Springs. The company previously raised around $232 million in total VC funding, including a $170 million Series A-1 round in 2005 that helped finance the $210 million acquisition of aaiPharma's pharmaceutical division out of bankruptcy. Last October, it canceled a proposed $86.25 million IPO due to “market conditions.”
- Week in deals, May 25, 2009
Summary of tech companies and other businesses that raised financing in North America in the past week
- Cempra Pharma Raises $46 Million
Cempra Pharmaceuticals Inc., a Chapel Hill, N.C.-based developer of anti-infectives, has raised $46 million in Series C funding. Quaker BioVentures led the round, and was joined by Devon Park Bioventures and return backers Aisling Capital, Intersouth Partners, Teachers’ Private Capital and investment banker I. Wistar Morris III. The company previously raised around $32 million.
- peHUB Wire: Thursday, May 14, 2009
Thursday Throwback
- peHUB Wire: Thursday, May 14, 2009
Thursday Throwback
Essex Woodlands Has Near-Perfect TimingLife sciences investor fell short of its goal, but still raised a record $900M
- Essex Woodlands raises $900M
Late stage life sciences investor falls a little short of goal
- Aisling closes on $650M
Former Perseus-Soros firm will invest in private and public companies with third life sciences fund
- Aisling raises $650M
Former Perseus-Soros firm nabs $650M for third life sciences fund